Article Contents ::
- 1 Details About Generic Salt :: Ranitid1
- 2 Main Medicine Class:: Histamine H2 antagonist,H. Pylori Agent
- 3 (ran-EYE-tih-DEEN BISS-muth) Tritec Class: Histamine H2 antagonist/H. Pylori Agent
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Ranitid1
Main Medicine Class:: Histamine H2 antagonist,H. Pylori Agent
(ran-EYE-tih-DEEN BISS-muth)
Tritec
Class: Histamine H2 antagonist/H. Pylori Agent
Drugs Class ::
Action Suppresses gastric acid secretion and bismuth, which may aid in Helicobacter pylori eradication. Used in combination with clarithromycin, a macrolide antibiotic.
Indications for Drugs ::
Indications Treatment of active duodenal ulcers associated with H. pylori infection when used in combination with clarithromycin. Eradication of this bacterium reduces the risk of ulcer recurrence.
Drug Dose ::
Route/Dosage
ADULTS: PO 400 mg bid for 28 days in conjunction with clarithromycin (Biaxin) 500 mg tid for the first 14 days.
Contraindication ::
Contraindications Standard considerations.
Drug Precautions ::
Precautions
Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established Porphyria: Do not use in patients with history of porphyria. Renal function impairment: Not recommended for use in patients with creatinine clearance < 25 ml/min or less. Treatment failure: Patients who fail to respond to therapy should not be retreated with a regimen containing clarithromycin.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CNS: Headache. GI: Diarrhea; constipation; benign dark or black coloration of the tongue or feces.
Drug Mode of Action ::
Action Suppresses gastric acid secretion and bismuth, which may aid in Helicobacter pylori eradication. Used in combination with clarithromycin, a macrolide antibiotic.
Drug Interactions ::
Interactions
Antacids: High doses lower ranitidine and possibly bismuth levels. Clarithromycin: Increased ranitidine and bismuth levels. However, the combination is indicated to eradicate H. pylori and is not likely to be clinically relevant.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history including drug history and any known allergies. Note renal impairment and history of acute porphyria.
- Monitor CBC, renal and liver function test results.
- Ensure that clarithromycin is used concurrently during first 14 days of therapy.
- Monitor the adverse effects and report significant findings to physician.
|
Drug Storage/Management ::
Administration/Storage
- Can be taken with or without food.
- Administer in combination with antibiotic agent (eg, clarithromycin) for first 14 days of therapy for the treatment of active duodenal ulcer.
- Refrigerate or store at room temperature. Protect from light in tightly closed container. Protect from moisture.
Drug Notes ::
Patient/Family Education
- Instruct the patient to take ranitidine bismuth citrate twice daily as prescribed.
- Inform patient that in order for therapy to work, clarithromycin must be taken tid for first 14 days of therapy.
- Instruct patient not to take otc medications without consulting healthcare provider.
- Instruct the patient not to take an antacid at the same time as this combination therapy. This action may result in a decrease in plasma concentration of both bismuth and ranitidine.
- Advise patient to complete full course of therapy even if symptoms have resolved.
- Inform patient of potential adverse effects and precautions associated with separate drugs in this combination therapy
- Advise patient that bismuth may cause a temporary darkening of the tongue and stool.
- Instruct patient not to confuse the stool darkening with blood in the stool (melena). Occult blood testing may be necessary.
- Instruct patient to report any signs of bleeding to primary care provider.
- Instruct patient to notify primary care provider of any adverse reactions.
- Instruct female patients to notify primary care provider if they are pregnant or plan to become pregnant.
- Advise patients not to breastfeed while taking this medication.